BEYOND-MM 002NCT07903636
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Overall Response Rate (ORR)
Timeframe: From the first dose to the end of Cycle 24 (each cycle is 28 days).
Secondary (8)
Extramedullary Disease Objective Response Rate (EMD-ORR)
Very Good Partial Response or Better Rate (≥VGPR Rate)
Complete Response or Stringent Complete Response Rate (CR/sCR Rate)
Time to Response (TTR)
Duration of Response (DoR)
Show 3 moreShow less
Progression-Free Survival (PFS)
Overall Survival (OS)
Incidence and Severity of Adverse Events (AEs)
Arms and interventions
QLS4131Experimental
Participants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles.
Drugs: QLS4131
Sites
1 site in 1 country
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, 300000Tianjin, China